slides · global inventory
List
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,471
Current window 90,571-90,600
Pages 3,683
Rows per page 30
Component
90,571-90,600 of 110,471
108
The chart uses a horizontal bar format to represent development progress against a timeline of stages (Target Eval to IND).Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
04
The slide uses a structured comparison layout to differentiate between individual programs and a combination strategy.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
12
Aeglea BioTherapeutics | Investor Presentation Deck | 37 slidesAeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
37
Includes a footnote regarding a 1-for-25 reverse stock split effective September 8, 2023.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
05
The chart is a scatter plot showing maintenance remission rates vs. dosing frequency, positioning current therapies in a cluster and the company's target in a superior quadrant.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
13
Aeglea BioTherapeutics | Investor Presentation Deck | 38 slidesAeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
38
Includes a footnote regarding a 1-for-25 reverse stock split effective September 8, 2023.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
12
Uses paw print icons as bullet points.AKT Pictures | Other Presentation Deck | 17 slides · akt-pictures
Deck Investor relations Beat · Need1 hit
03
Alkermes | Investor Presentation Deck | 37 slidesAlkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
05
The slide uses a numbered list format to present five key highlights about the company's spin-off status, cytokine portfolio, and specific drug program progress.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
13
Uses a before-after-framing style comparison to illustrate the mechanism of action differentiation.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · Solution1 hit
17
The slide presents clinical trial safety data (ARTISTRY-1) comparing monotherapy and combination therapy cohorts.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · Solution1 hit
20
The slide uses a timeline to track treatment milestones and CT scans to show tumor reduction from baseline to complete response.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · SolutionLoop · Before After1 hit
21
Includes a swimmer plot (left) and a summary table (right) with clinical trial metrics.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Loop · Before After1 hit
23
Clinical trial design diagram showing randomization, arms, dosing schedules, and endpoints.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
24
The slide uses a hub-and-spoke diagram for the mechanistic combinations.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
27
The slide uses a process diagram to show the IL-18 signaling cascade (IL-18 -> MYD88 -> IRAK -> NFkB -> IFNy) and a numbered list to detail its immunomodulatory functions.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
28
Uses a combination of a scatter plot and biological mechanism diagrams to illustrate the inhibitory effect of IL-18BP.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
29
Uses a before-after-bridge framework to illustrate the mechanism of action for the therapeutic candidate.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
31
The slide uses a diagram to illustrate the activation of immune cells (NKT, NK, CD4, CD8) by IL-12, leading to IFN-gamma production and subsequent downstream effects.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
32
The slide uses a process flow diagram to explain the therapeutic mechanism.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
35
Includes a footnote regarding patient enrollment for clinical milestones.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · Financials1 hit
36
Uses a numbered list format to highlight key company facts.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · Financials1 hit
06
Includes both GAAP and non-GAAP projections, plus specific product revenue breakdowns.Alkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations 1 hit
09
Includes a disclaimer regarding the forward-looking nature of the expectations.Alkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Solution1 hit
10
The chart tracks TRx (Total Prescriptions) over 101 weeks.Alkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Solution1 hit
11
Alkermes | Results Presentation Deck | 27 slidesAlkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Solution1 hit
12
Alkermes | Results Presentation Deck | 27 slidesAlkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Solution1 hit
15
The slide illustrates the escalation of doses for both SAD and MAD study arms.Alkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Market Size1 hit
16
SAD: Single Ascending Dose; MAD: Multiple Ascending Dose; AE: Adverse Event; SAE: Serious Adverse Event.Alkermes | Results Presentation Deck | 27 slides · Alkermes
Conference presentation Investor relations Beat · Market Size1 hit